ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
HARRY DASSAH M.D.

Cardiovascular Disease

3,549

$150K

149
123 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

13%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 28%

$42
Average prescription price

Avg: $67

SONIA SAWAL M.D.

Cardiovascular Disease

12,256

$508K

463
418 are 65+

8%
patients receiving schedule two controlled substances

Avg: 0%

28%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 28%

$41
Average prescription price

Avg: $67

PAUL MILLER MD

Cardiovascular Disease

5,514

$191K

297
268 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

10%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 28%

$35
Average prescription price

Avg: $67

BYRON SONG MD

Cardiovascular Disease

4,104

$112K

173
164 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

8%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 28%

$27
Average prescription price

Avg: $67

KENNETH TYE M.D.

Cardiovascular Disease

4,115

$191K

275
254 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$46
Average prescription price

Avg: $67

VINOD MALHOTRA MD

Cardiovascular Disease

10,188

$531K

478
340 are 65+

9%
patients receiving schedule two controlled substances

Avg: 0%

22%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 28%

$52
Average prescription price

Avg: $67

IDUAMA KELLY-DOKUBO M.D.

Cardiovascular Disease

6,799

$338K

198
176 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$50
Average prescription price

Avg: $67

BAO YANG MD

Cardiovascular Disease

1,007

$43K

76
68 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 28%

$43
Average prescription price

Avg: $67

PRAMOD MULTANI MD

Cardiovascular Disease

21,714

$1.21M

781
673 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

16%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$56
Average prescription price

Avg: $67

STEWART FRANK M.D.

Cardiovascular Disease

10,053

$396K

422
375 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

18%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 28%

$39
Average prescription price

Avg: $67

JACOB RUBIN M.D.

Cardiovascular Disease

3,163

$241K

280
238 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

39%
prescriptions for brand name drugs

Avg: 28%

$76
Average prescription price

Avg: $67

JIJIBHOY PATEL MD

Cardiovascular Disease

2,175

$189K

52
31 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$87
Average prescription price

Avg: $67

MOHD. QAISAR KHAN MD

Cardiovascular Disease

5,738

$244K

192
173 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$43
Average prescription price

Avg: $67

HERBERT STEIN M.D.

Cardiovascular Disease

2,786

$219K

146
133 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$79
Average prescription price

Avg: $67

ROBERT DAVIDSON M.D

Cardiovascular Disease

3,399

$266K

190
174 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$78
Average prescription price

Avg: $67

HYGIN ANDREW MD

Cardiovascular Disease

4,290

$266K

308
257 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$62
Average prescription price

Avg: $67

JOHN HAROLD MD

Cardiovascular Disease

1,368

$97.4K

141
135 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$71
Average prescription price

Avg: $67

MADHUSUDHAN GUPTA M.D.

Cardiovascular Disease

6,319

$321K

455
386 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$51
Average prescription price

Avg: $67

MINH NGUYEN MD

Cardiovascular Disease

20,502

$1.26M

706
598 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 28%

$61
Average prescription price

Avg: $67

STANLEY LAU M.D.

Cardiovascular Disease

11,873

$515K

1222
1157 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 28%

$43
Average prescription price

Avg: $67

ROBERT KARNS M.D.

Cardiovascular Disease

2,082

$168K

218
174 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

15%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 28%

$80
Average prescription price

Avg: $67

GUSTAVO MONDRAGON M.D.

Cardiovascular Disease

15,979

$572K

596
514 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$36
Average prescription price

Avg: $67

DAVID SCHIFF M.D.

Cardiovascular Disease

4,421

$246K

168
105 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

17%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$56
Average prescription price

Avg: $67

JULIAN JACOBS M.D.

Cardiovascular Disease

1,403

$155K

59
57 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 28%

$111
Average prescription price

Avg: $67

JIUNN PERNG M.D.

Cardiovascular Disease

4,933

$302K

172
150 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$61
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank